When yervoy ran out of patent?

When did Yervoy (ipilimumab) patent protection run out?

Yervoy (ipilimumab) is protected by multiple patents covering different aspects of the drug (composition, formulations, and related IP). Because of that, “the patent” does not end on a single date. Instead, generic or biosimilar timelines are driven by the latest expiring patent(s) and any exclusivity that applies.

DrugPatentWatch.com tracks Yervoy’s patent status and expiration dates across its patent families, which is the most direct way to see when the relevant protection periods end. You can view those details here: https://www.drugpatentwatch.com/p/yervoy-8/ [1]

Why “patent ran out” can mean different dates

Even when one patent expires, other patents or exclusivity protections can still block entry or delay approval of competitors. Users often see different dates online because they refer to:
- the first patent expiration vs. the last (often the last one matters most for competition), or
- different jurisdictions (US vs. EU), or
- different exclusivity types (patent vs. regulatory/marketing exclusivity).

DrugPatentWatch.com’s patent-by-patent view helps reconcile these differences by showing which protections expire when. [1]

What to check if you want the exact “earliest likely entry” date

If you’re trying to predict when a generic/biosimilar could launch, check:
- the latest-expiring patent family covering the product, and
- whether any data exclusivity or other regulatory exclusivity extends the effective barrier after patent expiration.

Those details are also listed in the DrugPatentWatch.com entry for Yervoy. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/yervoy-8/